Thermo Fisher Strengthens Asian Bioprocessing With New Hyderabad Centre and Regional Hubs In Korea And Singapore; Tri-Hub Network Boosts Support For Asia’s Biomanufacturing Sector

Thermo Fisher Scientific has strengthened its bioprocessing presence in Asia with the launch of a new Bioprocess Design Center in Hyderabad, India, and expansions of its existing centers in Incheon, Korea, and Singapore. These investments align with the region’s growing demand for biologics, vaccines, and advanced modalities, including cell and gene therapies. By expanding its footprint, the company aims to bring cutting-edge bioprocessing technologies and localized expertise closer to Asian biopharma innovators.

The updated tri-hub network is designed to help customers rapidly design, test, and optimize biomanufacturing processes. In Incheon, the expanded Bioprocess Design Center provides enhanced laboratory infrastructure, advanced materials, and greater collaborative capabilities. The new center in Hyderabad, established in partnership with the Government of Telangana, offers dedicated spaces for process simulation, optimization, and co-development using state-of-the-art single-use and hybrid systems, strengthening India’s growing biomanufacturing ecosystem.

“Asia continues to play an increasingly important role in advancing innovation across the global biopharma industry,” said Daniella Cramp, Senior Vice President and President, BioProduction at Thermo Fisher Scientific. “By expanding our network in Korea, Singapore and India, we’re bringing world-class infrastructure and expertise closer to our customers, helping them deliver high-quality biologics faster, more cost-effectively and more sustainably.”

Singapore’s upgraded center supports end-to-end process development, offering bench-to-pilot scale capabilities, expert-led training, and close collaboration with technical specialists. Collectively, these three hubs ensure streamlined access to innovation, scalability, and operational agility, enabling faster and more sustainable biologics production across the region.

“Through advanced manufacturing, strategic partnerships and targeted regional investments, we are redefining what is possible in biologics production,” added Tony Acciarito, President, Asia Pacific and Middle East, Africa at Thermo Fisher Scientific. “We are proud to contribute to the transformation of Asia’s biopharma ecosystem and help our customers bring life-changing therapies to patients across Asia and beyond.”

Thermo Fisher continues to support the full biopharma value chain through its diverse portfolio, which spans next-generation sequencing, mass spectrometry, analytical instruments, and integrated bioprocessing systems. These end-to-end capabilities empower customers from early research to full-scale commercial manufacturing.